Nurix therapeutics awarded innovation passport for entry into innovative licensing and access pathway (ilap) in the united kingdom for nx-1607

Nx-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types

NRIX Ratings Summary

NRIX Quant Ranking